Compounds > arylomycin a-c16
Page last updated: 2024-11-13

arylomycin a-c16

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID54586211
CHEMBL ID1784531
SCHEMBL ID14234622
MeSH IDM0575045

Synonyms (4)

Synonym
CHEMBL1784531
arylomycin c16
bdbm50441139
SCHEMBL14234622
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Signal peptidase IEscherichia coli K-12IC50 (µMol)0.07000.07000.07000.0700AID773491
Signal peptidase IBStaphylococcus aureusIC50 (µMol)1.80001.80001.80001.8000AID773490
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Signal peptidase IEscherichia coli K-12Kd0.50900.03900.50900.9790AID1064481; AID1064482
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
signal peptide processingSignal peptidase IEscherichia coli K-12
proteolysisSignal peptidase IEscherichia coli K-12
protein processingSignal peptidase IEscherichia coli K-12
signal peptide processingSignal peptidase IEscherichia coli K-12
proteolysisSignal peptidase IEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
endopeptidase activitySignal peptidase IEscherichia coli K-12
serine-type endopeptidase activitySignal peptidase IEscherichia coli K-12
peptidase activitySignal peptidase IEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneSignal peptidase IEscherichia coli K-12
membraneSignal peptidase IEscherichia coli K-12
plasma membraneSignal peptidase IEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID1064481Binding affinity to full length His-tagged Escherichia coli PAS0232 SPase 1 P84S mutant expressed in Escherichia coli BL21 (DE3)2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID773490Binding affinity to Staphylococcus aureus type-1 signal peptidase using decanoyl-LSSPAYNO2A-ADKabzPD and decanyol-LTPTAYNO2A-ASKKabzDD as substrate by fluorescence assay2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Efforts toward broadening the spectrum of arylomycin antibiotic activity.
AID612072Antibacterial activity against wild-type Staphylococcus aureus NCTC 8325 after 24 hrs by CLSI broth microdilution method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Initial efforts toward the optimization of arylomycins for antibiotic activity.
AID601581Antibacterial activity against 1 x 10'7 CFU/mL Rhodococcus equi ATCC 6939 in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID601137Antibacterial activity against 1 x 10'7 CFU/mL wild-type Staphylococcus epidermidis RP62A in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID612074Antibacterial activity against wild-type Pseudomonas aeruginosa PAO1 after 24 hrs by CLSI broth microdilution method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Initial efforts toward the optimization of arylomycins for antibiotic activity.
AID773489Antibacterial activity against wild type Staphylococcus epidermidis RP62A assessed as growth inhibition after 22 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Efforts toward broadening the spectrum of arylomycin antibiotic activity.
AID601135Antibacterial activity against 1 x 10'7 CFU/mL Escherichia coli MG1655 PAS0260 harboring LepB P84L mutant in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID1064482Binding affinity to full length His-tagged Escherichia coli MG1665 SPase 1 expressed in Escherichia coli BL21 (DE3)2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID601576Antibacterial activity against 1 x 10'7 CFU/mL Corynebacterium glutamicum ATCC 44475 in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID612073Antibacterial activity against Escherichia coli MG1655 after 24 hrs by CLSI broth microdilution method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Initial efforts toward the optimization of arylomycins for antibiotic activity.
AID1696168Antimicrobial activity against Escherichia coli K-12 assessed as reduction in microbial growth after 24 hrs by CLSI based broth microdilution method2020Journal of natural products, 07-24, Volume: 83, Issue:7
Initial Analysis of the Arylomycin D Antibiotics.
AID773487Antibacterial activity against wild type methicillin-resistant Staphylococcus aureus USA300 assessed as growth inhibition after 22 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Efforts toward broadening the spectrum of arylomycin antibiotic activity.
AID773491Binding affinity to Escherichia coli type-1 signal peptidase lepB using decanoyl-LSSPAYNO2A-ADKabzPD and decanyol-LTPTAYNO2A-ASKKabzDD as substrate by fluorescence assay2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Efforts toward broadening the spectrum of arylomycin antibiotic activity.
AID1064484Antibacterial activity against Escherichia coli PAS0232 harboring SPase P84S mutant assessed as growth inhibition after 24 hrs by micro-broth dilution method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID601133Antibacterial activity against 1 x 10'7 CFU/mL Staphylococcus epidermidis RP62A PAS9002 harboring Sps1B-S31P mutant in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID1916634Antibacterial activity against Staphylococcus epidermidis ATCC 35984 assessed as bacterial cell growth inhibition measured after 18 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Bacterial type I signal peptidase inhibitors - Optimized hits from nature.
AID773484Antibacterial activity against Escherichia coli MG1655 harboring lepB (P84L) mutation assessed as growth inhibition after 22 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Efforts toward broadening the spectrum of arylomycin antibiotic activity.
AID601139Antibacterial activity against 1 x 10'7 CFU/mL wild-type Escherichia coli MG1655 in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID773483Antibacterial activity against Escherichia coli MG1655 harboring lptD mutation assessed as growth inhibition after 22 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Efforts toward broadening the spectrum of arylomycin antibiotic activity.
AID1354446Antimicrobial activity against Yersinia pestis KIM6+ harboring arabinose inducible type 1 signal peptidase in presence of 2% arabinose2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Optimization of a β-Lactam Scaffold for Antibacterial Activity via the Inhibition of Bacterial Type I Signal Peptidase.
AID1696169Antimicrobial activity against Escherichia coli IMP BAS901 assessed as reduction in microbial growth after 24 hrs by CLSI based broth microdilution method2020Journal of natural products, 07-24, Volume: 83, Issue:7
Initial Analysis of the Arylomycin D Antibiotics.
AID601577Antibacterial activity against 1 x 10'7 CFU/mL Streptococcus pneumoniae R800 in Todd Hewitt broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID601580Antibacterial activity against 1 x 10'7 CFU/mL Rhodococcus opacus DSM 1069 in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID773482Antibacterial activity against Escherichia coli MG1655 harboring lptD lepB (P84L) mutation assessed as growth inhibition after 22 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Efforts toward broadening the spectrum of arylomycin antibiotic activity.
AID1916635Antibacterial activity against Staphylococcus epidermidis assessed as bacterial cell growth inhibition2022European journal of medicinal chemistry, Aug-05, Volume: 238Bacterial type I signal peptidase inhibitors - Optimized hits from nature.
AID612066Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate USA3002011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Initial efforts toward the optimization of arylomycins for antibiotic activity.
AID612068Antibacterial activity against Staphylococcus aureus NCTC 8325 harboring lepB P29S mutant after 24 hrs by CLSI broth microdilution method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Initial efforts toward the optimization of arylomycins for antibiotic activity.
AID1696170Antimicrobial activity against methicillin-resistant Staphylococcus aureus USA300 assessed as reduction in microbial growth after 24 hrs by CLSI based broth microdilution method2020Journal of natural products, 07-24, Volume: 83, Issue:7
Initial Analysis of the Arylomycin D Antibiotics.
AID1916633Antibacterial activity against Escherichia coli assessed as bacterial cell growth inhibition2022European journal of medicinal chemistry, Aug-05, Volume: 238Bacterial type I signal peptidase inhibitors - Optimized hits from nature.
AID612067Antibacterial activity against wild-type Staphylococcus epidermidis RP62A after 24 hrs by CLSI broth microdilution method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Initial efforts toward the optimization of arylomycins for antibiotic activity.
AID612070Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring lepB P84L mutant after 24 hrs by CLSI broth microdilution method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Initial efforts toward the optimization of arylomycins for antibiotic activity.
AID612069Antibacterial activity against Escherichia coli MG1655 harboring lepB P84L mutant after 24 hrs by CLSI broth microdilution method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Initial efforts toward the optimization of arylomycins for antibiotic activity.
AID1064458Ratio of MIC for Staphylococcus epidermidis PAS9001 harboring SPase S92P mutant to MIC for wild type Staphylococcus epidermidis RP62A2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID1064485Antibacterial activity against Staphylococcus aureus PAS8001 harboring SPase P29S mutant assessed as growth inhibition after 24 hrs by micro-broth dilution method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID1916632Antibacterial activity against Escherichia coli MG1655 assessed as bacterial cell growth inhibition measured after 18 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Bacterial type I signal peptidase inhibitors - Optimized hits from nature.
AID1064486Antibacterial activity against wild type Staphylococcus epidermidis RP62A assessed as growth inhibition after 24 hrs by micro-broth dilution method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID601582Antibacterial activity against 1 x 10'6 CFU/mL Brevibacillus brevis ATCC 8246 in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID1354447Antimicrobial activity against Yersinia pestis KIM6+ harboring arabinose inducible type 1 signal peptidase2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Optimization of a β-Lactam Scaffold for Antibacterial Activity via the Inhibition of Bacterial Type I Signal Peptidase.
AID601141Antibacterial activity against 1 x 10'7 CFU/mL Lactococcus lactis ATCC 19257 in trypticase soy yeast broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID601578Antibacterial activity against 1 x 10'7 CFU/mL Streptococcus pyogenes M1-5448 in Todd Hewitt broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID773486Antibacterial activity against wild type Escherichia coli MG1655 assessed as growth inhibition after 22 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Efforts toward broadening the spectrum of arylomycin antibiotic activity.
AID601579Antibacterial activity against 1 x 10'7 CFU/mL Streptococcus agalactiae COH1 after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID1696167Antimicrobial activity against Staphylococcus epidermidis RP62A assessed as reduction in microbial growth after 24 hrs by CLSI based broth microdilution method2020Journal of natural products, 07-24, Volume: 83, Issue:7
Initial Analysis of the Arylomycin D Antibiotics.
AID1064459Antibacterial activity against Staphylococcus epidermidis PAS9001 harboring SPase S92P mutant assessed as growth inhibition after 24 hrs by micro-broth dilution method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID1064483Antibacterial activity against Pseudomonas aeruginosa PAS2006 harboring SPase P84S mutant assessed as growth inhibition after 24 hrs by micro-broth dilution method2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID773488Antibacterial activity against wild type methicillin-sensitive Staphylococcus aureus 8325 assessed as growth inhibition after 22 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Efforts toward broadening the spectrum of arylomycin antibiotic activity.
AID601134Antibacterial activity against 1 x 10'7 CFU/mL Pseudomonas aeruginosa PAO1 PAS2008 harboring LepB P84L mutant in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID601138Antibacterial activity against 1 x 10'7 CFU/mL wild-type Pseudomonas aeruginosa PAO1 in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID1696166Antimicrobial activity against Yersinia pestis KIM6+ assessed as reduction in microbial growth after 24 hrs by CLSI based broth microdilution method2020Journal of natural products, 07-24, Volume: 83, Issue:7
Initial Analysis of the Arylomycin D Antibiotics.
AID773485Antibacterial activity against Staphylococcus aureus 8325 harboring spsB (P29S) mutation assessed as growth inhibition after 22 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Efforts toward broadening the spectrum of arylomycin antibiotic activity.
AID612071Antibacterial activity against Staphylococcus epidermidis RP62A harboring spsB S29P mutant after 24 hrs by CLSI broth microdilution method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Initial efforts toward the optimization of arylomycins for antibiotic activity.
AID601136Antibacterial activity against 1 x 10'7 CFU/mL Staphylococcus aureus NCTC 8325 PAS8001 harboring SpsB P29S mutant in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
AID601140Antibacterial activity against 1 x 10'7 CFU/mL wild-type Staphylococcus aureus NCTC 8325 in cation-adjusted Mueller Hinton 2 broth after 24 hrs by CLSI broth microdilution method2011Journal of natural products, May-27, Volume: 74, Issue:5
Synthesis and biological characterization of arylomycin B antibiotics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (71.43)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.48 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
sch 34343
Sch 34343: structure given in first source; RN given refers to (5R-(5alpha,6alpha))-isomer		2.1710
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.1710beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
sorafenib
[no description available]		3.5110(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
myxovirescin a
myxovirescin A: from Myxococcus virescens; structure given in first source		3.1910
kibdelomycin
kibdelomycin: an antibiotic that inhibits both gyrase and DNA topoisomerase IV; isolated from Kibdelosporangium; structure in first source		3.1910
ConditionIndicatedRelationship StrengthStudiesTrials